Table 1.
Characteristics of CLL patients.
| Patient | Sex | Age | Diagnose | Leukocytes/ml | Lymphocytes/ml | CD5 | CD10 | CD19 | CD23 | FMC | CD38 | Surface chain | Cytogenetic/FISH | Prior treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 82 | CLL-B | 70.100 | 63.300 | + | − | + | + | − | − | Kappa | 13q | Untreated |
| 2 | M | 66 | CLL-B | 57.940 | 52.800 | + | − | + | + | − | Lambda | Untreated | ||
| 3 | F | 69 | CLL-B | 40.390 | 34.700 | + | − | + | − | Negative | 13q | Untreated | ||
| 4 | M | 73 | CLL-B | 9.930 | 3.400 | + | − | + | − | Kappa | Untreated | |||
| 5 | M | 61 | CLL-B | 18.740 | 15.500 | + | − | + | + | − | Kappa | No mutation | Untreated | |
| 6 | M | 84 | CLL-B | 28.050 | 22.000 | + | − | + | + | − | + | Kappa | Untreated |
All of them present CD19 receptor and they were not treated before the collection of the sample. FMC refers to FMC-7 antigen, which is an epitope of CD20.